Chimerix - CMRX Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1-year price targets for Chimerix's stock. Their CMRX share price forecasts range from $6.00 to $11.00. On average, they anticipate the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 574.6% from the stock's current price.
View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts.

Chimerix's stock was trading at $1.86 at the beginning of 2023. Since then, CMRX stock has decreased by 32.3% and is now trading at $1.26.
View the best growth stocks for 2023 here.

Chimerix saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,290,000 shares, an increase of 17.5% from the February 28th total of 2,800,000 shares. Based on an average daily trading volume, of 745,700 shares, the short-interest ratio is currently 4.4 days. Currently, 4.4% of the company's stock are short sold.
View Chimerix's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our CMRX earnings forecast.

Chimerix, Inc. (NASDAQ:CMRX) released its earnings results on Thursday, March, 2nd. The biopharmaceutical company reported ($0.24) EPS for the quarter, meeting analysts' consensus estimates of ($0.24). The biopharmaceutical company earned $0.81 million during the quarter, compared to the consensus estimate of $2.60 million. Chimerix had a trailing twelve-month return on equity of 113.54% and a net margin of 509.01%. During the same quarter in the previous year, the company posted ($0.45) earnings per share.

ETFs with the largest weight of Chimerix (NASDAQ:CMRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD).

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (3.63%), Monaco Asset Management SAM (2.62%), AQR Capital Management LLC (1.92%), Geode Capital Management LLC (1.79%), Millennium Management LLC (1.46%) and Morgan Stanley (0.88%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole and Robert J Meyer.
View institutional ownership trends.

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CMRX stock can currently be purchased for approximately $1.26.

Chimerix (NASDAQ:CMRX) has a market capitalization of $111.22 million and generates $33.82 million in revenue each year. The biopharmaceutical company earns $172.17 million in net income (profit) each year or $1.96 on an earnings per share basis.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.